AnishKaushikVaniMD

PubMed

• 16 citations
  Prevention of atherosclerotic cardiovascular disease in South Asians in the US: A clinical perspective from the National Lipid Association
  Dinesh Kalra, Krishnaswami Vijayaraghavan, Geeta Sikand, Nihar R. Desai, Parag H. Joshi, Anurag Mehta, Wahida Karmally, Anish Vani, Shoeb Sitafalwalla, Raman Puri, P. ...> ;Journal of Clinical Lipidology. 2021 May 1
• 7 citations
  Leveraging clinical decision support tools to improve guideline-directed medical therapy in patients with atherosclerotic cardiovascular disease at hospital discharge.
  Anish Vani, Karen Kan, Eduardo Iturrate, Dina Levy-Lambert, Nathaniel R. Smilowitz, Archana Saxena, Martha J. Radford, Eugenia Gianos> ;Cardiology Journal. 2020 Sep 21
• 1 citations
  A case of nonvalvular endocarditis with biventricular apical infected thrombi.
  Anish Vani, Monica Ahluwalia, Robert Donnino, Albert Jung, Mikhail Vaynblat, Larry A. Latson, Muhamed Saric> ;Echocardiography. 2020 Jul 1
• 14 citations
  Cardiovascular Risk Factor Control and Lifestyle Factors in Young to Middle-Aged Adults with Newly Diagnosed Obstructive Coronary Artery Disease.
  Michael S. Garshick, Georgeta Vaidean, Anish Vani, James A. Underberg, Jonathan D. Newman, Jeffrey S. Berger, Edward A. Fisher, Eugenia Gianos> ;Cardiology. 2019 Jan 1
• 56 citations
  The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review.
  Jonathan D. Newman, Anish Vani, Jose O. Aleman, Howard Weintraub, Jeffrey S. Berger, Arthur Schwartzbard> ;Journal of the American College of Cardiology. 2018 Oct 9
• Biomarkers as Surrogates for Coronary Endothelial Dysfunction in Patients With Nonobstructive Coronary Artery Disease.
  Anish Vani, Arthur Schwartzbard, Howard Weintraub> ;Journal of the American Heart Association. 2018 Aug 7
• 5 citations
  Lowering LDL-Cholesterol and CV Benefits: Is There a Limit to How Low LDL-C Needs to be for Optimal Health Benefits?
  Anish Vani, James A. Underberg> ;Clinical Pharmacology and Therapeutics. 2018 Aug 1
• 5 citations
  Prevalence of unrecognized diabetes, prediabetes and metabolic syndrome in patients undergoing elective percutaneous coronary intervention
  Revathi Balakrishnan, Jeffrey S. Berger, Lisa Tully, Anish Vani, Binita Shah, Joseph Burdowski, Edward A. Fisher, Arthur Schwartzbard, Steven P. Sedlis, Howard Weintra...> ;Diabetes/metabolism Research and Reviews. 2015 Sep 1
• 10 citations
  Suboptimal risk factor control in patients undergoing elective coronary or peripheral percutaneous intervention.
  Lisa Tully, Eugenia Gianos, Anish Vani, Yu Guo, Revathi Balakrishnan, Arthur Schwartzbard, James Slater, James A. Underberg, Howard Weintraub, Edward A. Fisher, Jeffre...> ;American Heart Journal. 2014 Sep 1
• 67 citations
  Deficiency of Suppressor Enhancer Lin12 1 Like (SEL1L) in Mice Leads to Systemic Endoplasmic Reticulum Stress and Embryonic Lethality
  Adam B. Francisco, Rajni Singh, Shuai Li, Anish K. Vani, Liu Yang, Robert J. Munroe, Giuseppe R. Diaferia, Marina Cardano, Ida Biunno, Ling Qi, John C. Schimenti, Qiao...> ;The Journal of Biological Chemistry. 2010 Apr 30
• Join now to see all

Journal Articles

• The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction  
  Arthur Z Schwartzbard, Jonathan D Newman, Howard S Weintraub, Jeffrey S Berger, Anish K Vani, ScienceDirect
• Lowering LDL‐Cholesterol and CV Benefits: Is There a Limit to How Low LDL‐C Needs to Be for Optimal Health Benefits?  
  Anish Vani, James A Underberg, Clinical Pharmacology & Therapeutics